Drug Profile
ZSP 1241
Alternative Names: ZSP1241Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Guangdong Zhongsheng Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in China (PO, Tablet)
- 16 Nov 2018 Guangdong Zhongsheng Pharmaceutical plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in China in November 2018 (PO) (NCT03734926)
- 16 Nov 2018 Preclinical trials in Solid tumours in China (PO) (NCT03734926)